S.-B. Kim

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Medicine, Oncology, Surgery +13

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

Sara A. Hurvitz, S.-B. Kim, Wei‐Pang Chung et al. · ESMO Open · 2024 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases

Fabrice André, Javier Cortés, G. Curigliano et al. · Annals of Oncology · 2024 · 40 citations · Full text

Medicine, Pharmacology, Neuro-oncology +10

Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person–years of follow-up

S.-A. Kim, Hyojeong Moon, Jong‐Lyel Roh et al. · Clinical & Translational Oncology · 2017 · 32 citations

Medicine, Oncology, Pharmacotherapy +8